CURx picks up a Gilead cystic fibrosis drug ready for Phase III

San Diego startup CURx has paid an undisclosed sum to license an antiobitic developed by Gilead ($GILD), planning to launch a Phase III trial on the drug to treat lung infections in cystic fibrosis patients. The drug, a combination of fosfomycin and tobramycin, is designed to fight Pseudomonas aeruginosa infection, and, after a promising Phase II in CF patients, CURx figures it has a shot at approval. This is the inlicensing company's second deal, following a $21 million deal with Ligand ($LGND) to get its hands on a seizure medication. News

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.